Not exact matches
Important factors that could cause actual results to differ materially from those reflected
in such forward - looking statements and that should
be considered
in evaluating our outlook include, but
are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases
in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest
in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions
in the industries and markets
in which we operate
in the U.S. and globally and any changes therein, including fluctuations
in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain
in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment
manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both
in the U.S. and abroad; 20) the effect of changes
in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that
was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction
in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not
be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco
in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations
in foreign current exchange rates, impositions of tariffs or embargoes,
compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
Disclosure: Mike Moffatt
is the co-owner of Nexreg
Compliance, which provides regulatory consulting services to
manufacturers, including several
in the automotive industry.
X-ray inspection systems
are capable of determining mass that can provide an accurate total package weight to assist
manufacturers in meeting local weights and measures regulations for package weight
compliance.
Health claim legislation
is described and the ways
in which
manufacturers can ensure
compliance are discussed.
, and now allows companies which make add - on products for football helmets to make their own certification of
compliance with the NOCSAE standards on a helmet model, as long as the certification
is done according to NOCSAE standards, and as long as the
manufacturer assumes responsibility (
in other words, potential legal liability) for the helmet / add - on combination.
The long answer
is that, it
is true that the National Operating Committee on Standards for Athletic Equipment (NOCSAE) initially decided
in July 2013 that modification of helmets with third - party after - market add - ons, such as impact sensors installed inside a helmet or to its exterior, would
be viewed as voiding the helmet
manufacturer's certification, and that the certification could only
be regained if the helmet
was retested by the
manufacturer with the add - on, NOCSAE later issued a press release clarifying that position: Instead of automatically voiding the certification, NOCSAE decided it would leave it up to helmet
manufacturers to decide whether a particular third - party add - on affixed to the helmet, such as a impact sensor, voided its certification of
compliance with NOCSAE's standard, and now allows companies which make add - on products for football helmets to make their own certification of
compliance with the NOCSAE standards on a helmet model, as long as the certification
is done according to NOCSAE standards, and as long as the
manufacturer assumes responsibility (
in other words, potential legal liability) for the helmet / add - on combination.
The assumption
was that Anthem expected medical equipment suppliers and
manufacturers to absorb this cost change for customers, significantly reducing costs while allowing the insurance company to remain
in compliance with federal regulations.
• incorporate the provisions of COUNCIL RESOLUTION of 18 June 1992 on the marketing of breast - milk substitutes
in third countries by Community - based
manufacturers (92 / C 172/01) which encourages: «
compliance with the International Code of Marketing of Breast - milk Substitutes when these products
are placed on sale
in export markets,
in so far as this does not conflict with the provisions
in force
in the countries concerned» and offers EU «effective support to competent authorities to apply the International Code
in their territory.»
They also will not intervene on the
manufacturer's behalf to ensure that the products they
are selling
are in compliance with intellectual property laws.
The BC1 02 study additionally cited by the drug
manufacturer was not considered because radium - 223
was not used
in compliance with its approval
in this study.
Those of you who attended our SEMA Show seminar on emissions
compliance were reminded that the California Air Resources Board (CARB) and the U.S. Environmental Protection Agency (EPA) have the combined authority to enforce anti-tampering regulations
in all 50 states — and not just against
manufacturers but industry resellers as well.
Like the test maneuver
in the NPRM, the J - turn test maneuver
is among those available to
manufacturers to demonstrate
compliance with the UNECE mandate for ESC on trucks and buses.
Manufacturers that
are in compliance with NASC guidelines
are afforded the privilege of bearing the NASC Seal of Quality, which helps the
manufacturer establish credibility with retailers looking for trustworthy vendor partners
in this category.
Jessie,
is also one of the senior technicians,
is in charge of keeping the clinic
in compliance of OSHA regulations, organizing OSHA training for our staff and
is responsible for handling
manufacturer promotions and rebate program.
York continues, «The shelter's fan
is not
in compliance with 02 NCAC 52J.0605 Chamber Requirements:... (f) Any chamber electrical wiring or components exposed to carbon monoxide must
be warranted by the
manufacturer to
be explosion proof.»
Although basically all
manufacturers offer a model, the majority
are «
compliance cars», made
in tiny numbers and available only
in states (such as California) where they
are required to do so.
Plug -
in hybrids and electric vehicles sold will
be counted as multiple vehicles
in their
manufacturer's
compliance calculations.
In the pharmaceuticals manufacturers» efforts to gain as much promotional «noise» as possible from research conducted in compliance with FDA and EMEA requirements for marketing approval, this comes under the heading of publications planning, the extraction from available study data of as many additional articles and presentations as can be manage
In the pharmaceuticals
manufacturers» efforts to gain as much promotional «noise» as possible from research conducted
in compliance with FDA and EMEA requirements for marketing approval, this comes under the heading of publications planning, the extraction from available study data of as many additional articles and presentations as can be manage
in compliance with FDA and EMEA requirements for marketing approval, this comes under the heading of publications planning, the extraction from available study data of as many additional articles and presentations as can
be managed.
The program will require all products seeking the Energy Star label to
be tested
in approved labs and require
manufacturers to participate
in an ongoing verification testing program that will ensure continued
compliance.
Another would
be to have a term that states something like: «Due to the fact that it could pose an extreme danger to end users of this product if it does not exactly meet every specification set forth
in this contract, strict
compliance with every specification of this contract shall
be required and
manufacturer shall not
be entitled to any compensation under this contract if the Widgets produced hereunder have even slight or accidental defects even if the
manufacturer has substantially performed the work under this contract.»
The driver's log can
be useful
in determining the driver's
compliance with state and federal regulations regarding the number of hours driving time, total number of rest periods, the vehicle's inspection dates and the
manufacturer's recommended gross vehicle weight.
«The government clearly heard our perspective and adopted a balanced approach: There will
be limited patent - term extensions
in specified circumstances and a so - called «right of appeal» for brand - name
manufacturers in applications under the Patented Medicines (Notice of
Compliance) Regulations.»
The Blog
was one of the first
in the country to address legal issues facing
manufacturers and distributors and
is written by experienced lawyers covering issues concerning environmental, health, and safety / OSHA, labor and employment, and corporate
compliance and litigation.
Manufacturers must therefore ensure that they
are operating
in compliance with any new regulatory standards, show that past testing and confidentiality practices reflected a corporate commitment to safety and «playing by the rules,» and then communicate all this to judges and juries
in a compelling and comprehensible manner.